American Ginseng

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: energy focus immunity

Research Overview

Research on American ginseng (Panax quinquefolius) has focused most heavily on (i) phytochemistry and processing-related changes in bioactive constituents (especially ginsenosides/saponins, and to a growing extent polysaccharides), and (ii) preclinical efficacy in inflammation- and oxidative stress–related conditions. Multiple studies emphasize advanced analytical profiling (e.g., LC–MS metabolomics to catalog hundreds of saponins and identify markers that differ by species and preparation such as soaking/decoction) and extraction/purification innovations for polysaccharides (e.g., “green” deep eutectic solvent three-phase partitioning). Disease-model work is prominent, including immune/intestinal injury contexts, inflammatory models (macrophage cells; zebrafish neutrophil recruitment), gut-barrier dysfunction (Drosophila colitis-like models), and respiratory disease (cigarette smoke–induced COPD in mice), typically linking effects to reduced inflammatory signaling and oxidative stress.

The strongest evidence base in humans, as reflected in the clinical-review abstract, supports that ginseng preparations (including American ginseng) are generally safe when used as studied and may provide mild-to-moderate benefits as an adjunct for several outcomes (e.g., glycemic control/diabetes-related measures, aspects of cognition/mood, common cold/flu outcomes, cancer-related fatigue/well-being, and quality-of-life measures). Separately, an evidence synthesis on supplement–drug interactions characterizes American ginseng as having a relatively low likelihood of clinically important interactions with most medications (with caveats and the need for case-by-case assessment). In contrast, many mechanistic and disease-specific claims for American ginseng—such as anti-inflammatory activity via COX-2–related pathways for berry polysaccharides or protection in COPD models via oxidative stress/inflammation modulation—are currently supported primarily by in vitro and animal-model data rather than definitive clinical trials.

Key gaps include the need for more rigorous, well-controlled human trials specifically using standardized American ginseng products with detailed phytochemical characterization and quality control (dose, ginsenoside/polysaccharide profiles, and reproducible processing methods such as decoction time). Translational work is also needed to connect preclinical endpoints (e.g., cytokine changes, neutrophil recruitment, intestinal barrier markers, network-pharmacology targets) to clinically meaningful outcomes in conditions suggested by models (e.g., inflammatory bowel disease/colitis, COPD, chemotherapy-associated mucosal injury). Finally, further research should clarify which constituents (rare ginsenosides vs. defined polysaccharide fractions), preparations (root vs. berry; wild-simulated vs. field-grown), and patient subgroups drive observed effects, and should strengthen pharmacokinetic and real-world interaction surveillance to confirm safety across common medication regimens.

1. What conditions has American Ginseng been studied for?

  • Type 2 diabetes (T2DM) and cardiometabolic risk factors: Studied as an add-on to conventional therapy in a human clinical trial (HbA1c, fasting glucose, blood pressure, lipids).

  • Chronic obstructive pulmonary disease (COPD): Studied in a cigarette-smoke (CS) induced COPD mouse model using total saponins from American ginseng (wild-simulated and field-grown).

  • Inflammation (general anti-inflammatory activity): Studied using an isolated berry polysaccharide (AGBP-A) in vitro (RAW 264.7 macrophages) and in vivo (zebrafish inflammation model), including COX-2 docking.

  • Intestinal injury / intestinal barrier dysfunction and colitis models: American ginseng polysaccharides (AGP-DES-4) studied in vivo in a Drosophila ulcerative colitis (UC) model, focusing on intestinal barrier function and epithelial/stem cell regulation.

  • Viral respiratory infections / common cold and flu: A review of complementary therapies lists North American ginseng among remedies “found effective” for viral respiratory illnesses, but the study does not provide specific trial details.

  • Cognition/mood, cardiovascular disorders, cancer fatigue/well-being, quality of life: A broader clinical review of “ginseng” (not exclusively American ginseng) reports clinical studies across these areas; applicability specifically to American ginseng depends on which species was used in each trial.

  • Cancer-related contexts (preclinical): A review focused on American ginseng describes anti-cancer effects (e.g., apoptosis, reduced local inflammation) largely from experimental studies.

  • Chemotherapy-associated immunosuppression and intestinal mucosal damage (cyclophosphamide): Mentioned in a truncated abstract fragment; the provided text is insufficient to summarize outcomes.

2. Does it work in treating those conditions? Summarize the evidence.

  • T2DM (human clinical evidence; adjunctive use): In a trial of 24 people with T2DM on conventional treatment, American ginseng (AG) extract vs placebo significantly improved multiple endpoints:

    • HbA1c: −0.29% (p = 0.041)

    • Fasting blood glucose: −0.71 mmol/L (p = 0.008)

    • Systolic blood pressure: −5.6 ± 2.7 mmHg (p < 0.001)

    • Nitric oxide metabolites (NOx): +1.85 ± 2.13 µmol/L (p < 0.03)

    • Lipids: mean percent end-difference −12.3 ± 3.9% in LDL-C and −13.9 ± 5.8% in LDL-C/HDL

    Interpretation: Evidence supports modest improvements as an add-on therapy in this small study; the authors explicitly call for larger trials with physiologically standardized preparations.

  • COPD (animal evidence): In a CS-induced COPD mouse model, total saponins from American ginseng (both wild-simulated and field-grown) showed protective effects by alleviating oxidative stress and inflammatory response; wild-simulated appeared stronger than field-grown. Mechanistic approaches (metabolomics/network pharmacology) identified biomarkers/targets/pathways, and several compounds were proposed as contributors (e.g., ginsenoside Rg1, Rc, oleanolic acid, notoginsenoside R1, Fe, silphioside B).

    Interpretation: Promising preclinical evidence; not yet proof of clinical efficacy in humans with COPD.

  • Inflammation (cell + zebrafish evidence): A purified neutral berry polysaccharide (AGBP-A) reduced pro-inflammatory cytokines in RAW 264.7 cells and reduced neutrophil recruitment in a zebrafish inflammation model; docking suggested potential interaction with COX-2.

    Interpretation: Supports anti-inflammatory potential, but these are non-human models and do not establish clinical effectiveness.

  • Intestinal barrier dysfunction / UC model (Drosophila evidence): AGP-DES-4 improved survival in a UC fly model and enhanced intestinal barrier function, associated with regulation of intestinal epithelial cells (IECs) and intestinal stem cells (ISCs).

    Interpretation: Mechanistically interesting preclinical evidence; translation to human inflammatory bowel disease is uncertain.

  • Common cold/flu and other clinical outcomes (mixed ginseng evidence): A clinical review of ginseng trials over ~20 years reports generally “mild to moderate” benefits across conditions (including common cold/flu, cognition/mood, cardiovascular disorders, cancer fatigue/well-being, quality of life) and a good safety record. However, the study does not separate outcomes by ginseng species, dose standardization, or trial quality in detail.

3. What health benefits does it have?

  • Glycemic control (human evidence): In T2DM, AG extract improved HbA1c and fasting glucose when added to standard care in a small clinical study.

  • Blood pressure and vascular-related markers (human evidence): The same T2DM trial reported reduced systolic blood pressure and increased NOx (a nitric oxide-related measure), suggesting potential vascular/endothelial effects.

  • Lipid-related improvements (human evidence): The T2DM trial reported improvements in LDL-C and LDL-C/HDL ratio (reported as mean percent end-differences).

  • Anti-inflammatory activity (preclinical evidence): American ginseng berry polysaccharide (AGBP-A) reduced inflammatory signaling in macrophage cells and reduced neutrophil recruitment in zebrafish; COPD mouse work also supports anti-inflammatory effects of saponin mixtures.

  • Antioxidant/oxidative stress modulation (preclinical evidence): In COPD mice, total saponins alleviated oxidative stress alongside inflammation.

  • Gut barrier support (preclinical evidence): In a Drosophila UC model, extracted polysaccharides improved survival and intestinal barrier function and influenced IEC/ISC dynamics.

  • Potential broader “adaptogenic”/quality-of-life benefits (general ginseng clinical review): Clinical studies of ginseng (species not always specified in the study) suggest mild-to-moderate benefits for areas such as common cold/flu, cognition/mood, cancer fatigue/well-being, and quality of life/social functioning, with emphasis that future trials need better phytochemical characterization and quality control.

4. Does it have any downsides or side effects?

  • Safety in the cited T2DM trial: “Safety profiles were unaffected” in the 24-person add-on trial, suggesting no major short-term safety signal in that study.

  • Overall safety record in humans (general ginseng review): The clinical review states that ginseng administration demonstrated a “good safety record in humans,” with effects generally mild-to-moderate in magnitude.

  • Drug interaction risk (general supplement interaction review): A review on supplement–prescription interactions lists American ginseng among supplements with a low likelihood of drug interactions “with certain caveats,” but it does not claim zero risk and recommends consulting reliable resources/clinicians for specific combinations.

  • Important limitations of the studies reviewed here: The studies supplied do not enumerate specific adverse effects (e.g., insomnia, GI upset) or contraindications, nor do they provide long-term safety data, pregnancy/lactation safety, or detailed interaction data with specific drug classes.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic analyses (e.g., outcomes stratified by genotype) for American ginseng.

  • No genotype-stratified efficacy data: The T2DM clinical trial reports group-level improvements but does not mention genetic subgroups or responder genotypes.

  • No genotype-stratified safety/interaction data: The supplement–drug interaction review categorizes American ginseng as low-likelihood for interactions in general, but does not address genetic variants affecting metabolism/transport (e.g., CYP polymorphisms) or pharmacodynamic targets.

  • Practical implication: Based on these studies alone, there is insufficient evidence to claim American ginseng is specifically beneficial or harmful for particular genetic variants; any pharmacogenomic claims would require studies explicitly designed to test gene–supplement interactions.

American Ginseng Panax Quinquefolius

Research on American ginseng (Panax quinquefolius) spans metabolic, cardiovascular, immuno-inflammatory, and anticancer domains, with a strong emphasis on identifying bioactive constituents (notably ginsenosides such as Rg3 and polysaccharides) and elucidating mechanisms of action in cellular and animal models. Among the most studied areas are glycemic control in type 2 diabetes, vascular/blood pressure effects (often in the context of cardiometabolic risk), and anti-inflammatory or anticancer activities of isolated components. Mechanistic studies commonly focus on inflammatory mediator suppression (e.g., TNF-α, IL-6, IL-1β, nitric oxide) and cancer-relevant signaling pathways (e.g., Wnt/β-catenin), while pharmacology reviews highlight bioavailability limitations of native ginsenosides and explore metabolites/derivatives (e.g., panaxadiol/protopanaxadiol) as potentially more bioavailable scaffolds.

The strongest human evidence in the studies reviewed here supports modest improvements in glycemic indices when standardized American ginseng extract is used as an adjunct to conventional therapy in type 2 diabetes, including small but statistically significant reductions in HbA1c and fasting glucose, with no major safety signals reported in the short term. Clinical evidence also suggests a modest blood-pressure benefit in cardiometabolic populations, particularly when American ginseng is co-administered with Korean red ginseng preparations enriched in ginsenoside Rg3; reductions were observed in central systolic blood pressure and related waveform components, although measures of endothelial function and arterial stiffness did not clearly improve. In contrast, anticancer and anti-inflammatory findings—such as Rg3-mediated inhibition of β-catenin nuclear translocation in colon cancer models and suppression of pro-inflammatory cytokines by a neutral polysaccharide in macrophages—are currently supported primarily by in vitro and animal/xenograft data, indicating biological plausibility but not yet clinical efficacy.

Key gaps include the need for larger, well-controlled, longer-duration randomized trials of American ginseng alone (and clearly characterized combinations) using physiologically standardized preparations with verified ginsenoside/polysaccharide profiles, alongside rigorous pharmacokinetic characterization to address bioavailability and inter-product variability. Additional research is needed to determine dose–response relationships, durability of glycemic and blood-pressure effects, clinically meaningful endpoints (e.g., cardiovascular events), and subgroup effects (e.g., baseline control, concomitant medications). For oncology and inflammation-related indications, translation requires early-phase clinical studies to establish human-relevant exposure, target engagement, and safety in relevant populations, as well as clearer attribution of effects to specific constituents (e.g., Rg3 vs. polysaccharides) and their metabolites.

References

  1. The Synergistic Effects of Polysaccharides and Ginsenosides From American Ginseng (
    Rongrong Zhou, Dan He, Jing Xie, Qingyijun Zhou, Hongliang Zeng, Hongmei Li, Luqi Huang (2021) - Frontiers in immunology
  2. Pharmacological Effects of Ginseng: Multiple Constituents and Multiple Actions on Humans.
    Guolin Zhou, Chong-Zhi Wang, Somayeh Mohammadi, Wamtinga R Sawadogo, Qinge Ma, Chun-Su Yuan (2023) - The American journal of Chinese medicine
  3. Characterization of the structure, anti-inflammatory activity and molecular docking of a neutral polysaccharide separated from American ginseng berries.
    Qixiang Feng, Huijiao Yan, Yu Feng, Li Cui, Hidayat Hussain, Jeong Hill Park, Sung Won Kwon, Lei Xie, Yan Zhao, Zhihao Zhang, Jinfan Li, Daijie Wang (2024) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  4. Common Herbal Dietary Supplement-Drug Interactions.
    Gary N Asher, Amanda H Corbett, Roy L Hawke (2017) - American family physician
  5. Application of UPLC-Triple TOF-MS/MS metabolomics strategy to reveal the dynamic changes of triterpenoid saponins during the decocting process of Asian ginseng and American ginseng.
    Li-Hua Chen, You-Bo Zhang, Xiu-Wei Yang, Jing Xu, Zhao-Jing Wang, Yi-Zheng Sun, Wei Xu, Ying-Ping Wang (2023) - Food chemistry
  6. Extraction of American ginseng polysaccharide by ultrasound-assisted deep eutectic solvents-based three-phase partitioning: Process optimization, structural characterization, and anti-ulcerative colitis study.
    Zhongnan Wu, Chong Li, Junhao Li, Tanggan Wang, Meifeng Li, Leyi Zhao, Huimei Ye, Jiaheng Chen, Jiajia Zan, Lijun Song, Qian Zhang, Shaojie Zhang (2025) - Ultrasonics sonochemistry
  7. American Ginseng (Panax quinquefoliumL.) as a Source of Bioactive Phytochemicals with Pro-Health Properties
    Daria Szczuka, Adriana Nowak, Małgorzata Zakłos-Szyda, Ewa Kochan, Grażyna Szymańska (2019)
  8. Protective effect of total Saponins from American ginseng against cigarette smoke-induced COPD in mice based on integrated metabolomics and network pharmacology.
    Hongqiang Lin, Caixia Wang, Hui Yu, Yunhe Liu, Luying Tan, Shanmei He, Zhuoqiao Li, Cuizhu Wang, Fang Wang, Pingya Li, Jinping Liu (2022) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. Effect of Korean Red Ginseng on metabolic syndrome.
    Sang Jun Yoon, Seul Ki Kim, Na Young Lee, Ye Rin Choi, Hyeong Seob Kim, Haripriya Gupta, Gi Soo Youn, Hotaik Sung, Min Jea Shin, Ki Tae Suk (2021) - Journal of ginseng research
  10. Prevention and Treatment of Influenza, Influenza-Like Illness, and Common Cold by Herbal, Complementary, and Natural Therapies.
    Haider Abdul-Lateef Mousa (2017) - Journal of evidence-based complementary & alternative medicine
  11. Efficacy and safety of American ginseng (Panax quinquefolius L.) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial.
    Vladimir Vuksan, Zenith Zheng Xu, Elena Jovanovski, Alexandra L Jenkins, Uljana Beljan-Zdravkovic, John L Sievenpiper, P Mark Stavro, Andreea Zurbau, Lea Duvnjak, Michael Z C Li (2019) - European journal of nutrition
  12. Structural and anti-inflammatory characterization of a novel neutral polysaccharide from North American ginseng (Panax quinquefolius).
    Lijun Wang, Xiaona Yu, Xiushi Yang, Yi Li, Yang Yao, Edmund Man King Lui, Guixing Ren (2015) - International journal of biological macromolecules
  13. Chemical analysis of Panax quinquefolius (North American ginseng): A review.
    Yaping Wang, Hyung-Kyoon Choi, Josef A Brinckmann, Xue Jiang, Linfang Huang (2015) - Journal of chromatography. A
  14. Dammarane-type leads panaxadiol and protopanaxadiol for drug discovery: Biological activity and structural modification.
    Mingying Wang, Haonan Li, Weiwei Liu, Hao Cao, Xu Hu, Xiang Gao, Fanxing Xu, Zhanlin Li, Huiming Hua, Dahong Li (2020) - European journal of medicinal chemistry
  15. Therapeutic potential of ginseng in the management of cardiovascular disorders.
    Morris Karmazyn, Melissa Moey, Xiaohong Tracey Gan (2011) - Drugs
  16. Panax quinquefolius(North American Ginseng) Polysaccharides as Immunomodulators: Current Research Status and Future Directions
    Rajarshi Ghosh, Daniel L Bryant, Anthony L Farone (2020)
  17. Modulation of the hypothalamic-pituitary-adrenal (HPA) axis by plants and phytonutrients: a systematic review of human trials.
    Adrian L Lopresti, Stephen J Smith, Peter D Drummond (2022) - Nutritional neuroscience
  18. Hypoglycemic and Hypolipidemic Effects of Malonyl Ginsenosides from American Ginseng (
    Zhi Liu, Chun-Yuan Qu, Jia-Xin Li, Yan-Fang Wang, Wei Li, Chong-Zhi Wang, Dong-Sheng Wang, Jia Song, Guang-Zhi Sun, Chun-Su Yuan (2021) - ACS omega
  19. Effects of enzymatic hydrolysis technology on the physicochemical properties and biological activities of American ginseng beverages.
    Shengyuan Guo, Yichen Hu, Chaofan Zhao, Yajie Li, Zhuo Zhang, Wenting Wang, Yu Bai, Jiankang Zhou, Yajie Xue, Liang Zou, Guixing Ren (2024) - Food science & nutrition
  20. The correlations of adverse effect and tonifying effect of ginseng medicines.
    Xiaoku Ran, Deqiang Dou, Hongyu Chen, Guoqing Ren (2022) - Journal of ethnopharmacology
  21. Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ß-catenin signaling.
    Bai-Cheng He, Jian-Li Gao, Xiaoji Luo, Jinyong Luo, Jikun Shen, Linyuan Wang, Qixin Zhou, Yi-Tao Wang, Hue H Luu, Rex C Haydon, Chong-Zhi Wang, Wei Du, Chun-Su Yuan, Tong-Chuan He, Bing-Qiang Zhang (2011) - International journal of oncology
  22. Vascular effects of combined enriched Korean Red ginseng (Panax Ginseng) and American ginseng (Panax Quinquefolius) administration in individuals with hypertension and type 2 diabetes: A randomized controlled trial.
    Elena Jovanovski, Lea-Duvnjak-Smircic, Allison Komishon, Fei Au-Yeung, Andreea Zurbau, Alexandra L Jenkins, Mi-Kyung Sung, Robert Josse, Vladimir Vuksan (2020) - Complementary therapies in medicine
  23. Effect of coadministration of enriched Korean Red Ginseng (
    Elena Jovanovski, Lea Smircic-Duvnjak, Allison Komishon, Fei Rodney Au-Yeung, John L Sievenpiper, Andreea Zurbau, Alexandra L Jenkins, Mi-Kyung Sung, Robert Josse, Dandan Li, Vladimir Vuksan (2021) - Journal of ginseng research
  24. Ginseng and obesity: observations and understanding in cultured cells, animals and humans.
    Longyun Zhang, Carlos Virgous, Hongwei Si (2017) - The Journal of nutritional biochemistry
  25. Effect of American ginseng (Panax quinquefolius L.) on arterial stiffness in subjects with type-2 diabetes and concomitant hypertension.
    Iva Mucalo, Elena Jovanovski, Dario Rahelić, Velimir Božikov, Zeljko Romić, Vladimir Vuksan (2013) - Journal of ethnopharmacology
  26. Improved working memory performance following administration of a single dose of American ginseng (Panax quinquefolius L.) to healthy middle-age adults.
    Anastasia Ossoukhova, Lauren Owen, Karen Savage, Marjolaine Meyer, Alvin Ibarra, Marc Roller, Andrew Pipingas, Keith Wesnes, Andrew Scholey (2015) - Human psychopharmacology
  27. Characterization and In Vitro Antioxidant and Anti-Inflammatory Activities of Ginsenosides Extracted from Forest-Grown Wild
    Yang Yang, Shan Xu, Kemeng Yang, Yuning Sun, Ruirui Yang, Yanan Hu, Guijie Chen, Huimei Cai (2023) - Foods (Basel, Switzerland)
  28. Effects of maize rotation on the physicochemical properties and microbial communities of American ginseng cultivated soil.
    Xiao-Lin Jiao, Xue-Song Zhang, Xiao-Hong Lu, Ruijun Qin, Yan-Meng Bi, Wei-Wei Gao (2019) - Scientific reports
  29. A soil fumigant increases American ginseng (
    Na Peng, Yanmeng Bi, Xiaolin Jiao, Ximei Zhang, Junfei Li, Yi Wang, Shanshan Yang, Ziqi Liu, Weiwei Gao (2024) - Microbiology spectrum
  30. Comparison of Phytochemical Profiles of Wild and Cultivated American Ginseng Using Metabolomics by Ultra-High Performance Liquid Chromatography-High-Resolution Mass Spectrometry.
    Zhihao Liu, Roderick Moore, Ying Gao, Pei Chen, Liangli Yu, Mengliang Zhang, Jianghao Sun (2022) - Molecules (Basel, Switzerland)
  31. Complementary and alternative medicine for prevention and treatment of the common cold.
    Richard Nahas, Agneta Balla (2011) - Canadian family physician Medecin de famille canadien
  32. Distinct urine metabolome after Asian ginseng and American ginseng intervention based on GC-MS metabolomics approach.
    Liu Yang, Qing-Tao Yu, Ya-Zhong Ge, Wen-Song Zhang, Yong Fan, Chung-Wah Ma, Qun Liu, Lian-Wen Qi (2016) - Scientific reports
  33. The hypoglycemic effects of American red ginseng (Panax quinquefolius L.) on a diabetic mouse model.
    Kyung Mi Yoo, Cy Lee, Y Martin Lo, BoKyung Moon (2012) - Journal of food science


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!